6-KThe Wire
Alpha Tau Medical Ltd. files 6-K
Filed Jan 5, 2026 · 7mo ago · Accession 0001213900-26-000777
Plain English
Alpha Tau Medical Ltd. announced it submitted its first Pre-Market Approval Module to the FDA for its Alpha DaRT® technology for the treatment of recurrent cutaneous squamous cell carcinoma. This submission marks a significant step in the regulatory approval process for the Company's cancer treatment.
Filing details
- Company
- Alpha Tau Medical Ltd.
- Ticker
- DRTS
- CIK
- 1871321
- Form type
- 6-K
- Filing date
- Jan 5, 2026
- Report date
- Jan 5, 2026
- Document
- ea027162402-6k_alpha.htm
- Size
- 25 KB